TCGA-AO-A0J7-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.470
- OXIDATIVE_PHOSPHORYLATION+0.430
- G2M_CHECKPOINT+0.360
- DNA_REPAIR+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.310
- ESTROGEN_RESPONSE_EARLY+0.290
- ESTROGEN_RESPONSE_LATE+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.620
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.440
- KRAS_SIGNALING_UP-0.400
- COMPLEMENT-0.390
- IL2_STAT5_SIGNALING-0.370
- HEDGEHOG_SIGNALING-0.350
- TGF_BETA_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.925 |
| 2 | SRR4195654 | — | — | 0.918 |
| 3 | TCGA-EW-A2FW-01A-11R-A17B-07 | — | B | 0.906 |
| 4 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.903 |
| 5 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.894 |
| 6 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.891 |
| 7 | MDT-AP-0421 | Med | Medulloblastoma | 0.890 |
| 8 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.889 |
| 9 | C3N-01025 | — | cohortSQ2 | 0.889 |
| 10 | BSR_15_0056_E1_S102 | — | B | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |